A Study of LY3549492 in Healthy Weight Adult Participants

Not Applicable

Terminated

• Conditions: Healthy
• Interventions: Drug: LY3549492; Drug: Placebo

• Registration Number: NCT07085468
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in adult participants with a healthy body max index (BMI) of 22 to 25 kilograms per square meter (kg/m2).

Participation in the study will last about 13 months.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-07-18
• Study First Submitted QC: 2025-07-18
• Study Start: 2025-07-21
• Study First Posted: 2025-07-25
• Status Verified: 2025-08
• Primary Completion: 2025-08-14
• Study Completion: 2025-08-14
• Last Update Submitted: 2025-08-25
• Last Update Posted: 2025-08-29

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• Have a body mass index (BMI) within the range of 22 to 25 kilograms per square meter (kg/m2)
• Have had a stable body weight for 3 months prior to screening

Exclusion Criteria

• Have type 1 diabetes, latent autoimmune diabetes in adults, or a history of ketoacidosis or hyperosmolar coma

• Have:

  • type 2 diabetes and on antidiabetic therapy (except type 2 diabetes being managed with diet and/or stable dose of metformin)
  • rare forms of diabetes mellitus, or
  • hemoglobin A1c (HbA1c) >8%

• Have poorly controlled hypertension

• Have any of the following cardiovascular conditions within 12 months prior to screening:

  • acute myocardial infarction
  • stroke
  • unstable angina, or
  • hospitalization due to congestive heart failure.

• Have a history of New York Heart Association Functional Classification III or IV congestive heart failure

• Have signs and symptoms of liver disease

• Have a history of pancreatitis

• Have taken medications or alternative remedies for weight loss or weight gain within 3 months prior to screening

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
LY3549492 Dose 1	LY3549492	Participants will receive LY3549492 orally
LY3549492 Dose 2	LY3549492	Participants will receive LY3549492 orally
Placebo	Placebo	Participants will receive placebo orally

Primary Outcome Measures

Name	Time	Method
Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration	Baseline through Week 48	A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

Secondary Outcome Measures

Name	Time	Method
Percent Change from Baseline in Body Weight	Baseline, Week 24, Week 48
Number of Participants with Adverse Events Leading to Permanent Discontinuation of Study Intervention or Withdrawal	Baseline through Week 48

Trial Locations

Locations (19)

Headlands Research - Scottsdale; 🇺🇸 Scottsdale, Arizona, United States

Valley Clinical Trials, Inc.; 🇺🇸 Northridge, California, United States

Peninsula Research Associates; 🇺🇸 Rolling Hills Estates, California, United States

Artemis Institute for Clinical Research; 🇺🇸 San Diego, California, United States

JEM Research Institute; 🇺🇸 Atlantis, Florida, United States

Clinical Research Atlanta; 🇺🇸 Stockbridge, Georgia, United States

Great Lakes Clinical Trials - Andersonville; 🇺🇸 Chicago, Illinois, United States

Alliance for Multispecialty Research, LLC; 🇺🇸 Norman, Oklahoma, United States

Trial Management Associates; 🇺🇸 Myrtle Beach, South Carolina, United States

Viacar Recherche Clinique; 🇨🇦 Greenfield Park, Canada

Scroll for more (9 remaining)